Navigation Links
Human Genome Sciences Announces Proposed Public Offering of Common Stock
Date:7/27/2009

ROCKVILLE, Md., July 27 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has commenced an underwritten public offering of up to 18,000,000 shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 2,700,000 shares of the Company's common stock. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission on Form S-3.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

The Company intends to use net proceeds from the offering for general corporate purposes, including clinical trial, research and development, general and administrative and manufacturing expenses, as well as for potential sales and marketing activities. The Company may also use a portion of the proceeds for the potential acquisition of, or investment in, companies, products or technologies that complement our business. While the Company evaluates company, product, technology and similar opportunities from time to time, the Company currently has no material agreements or commitments with respect to any such acquisition or investment. The Company also may use a portion of the net proceeds to repay, repurchase or retire all or a portion of its 2 1/4% convertible subordinated notes due 2011 and 2 1/4% convertible subordinated notes due 2012.

Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint book-running managers for the offering.

This announcement shall not constitute an offer to sell or the solicita
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OMT announces a breakthrough in the development of a novel human antibody platform
2. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
3. Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
4. Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
5. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
6. Fruit fly steps in to fight human disease
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference
8. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
9. Assessment of safety and efficacy of human embryonic stem cell therapy
10. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
11. Printing New Organs: Foundation Funds Medical Technology That Replicates Human Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... SHANGHAI, June 29 /PRNewswire-Asia/ -- Sundia MediTech Company, ... Shanghai,China announced today that Dr. Tong Xu has been ... Prior to joining Sundia, Dr. Xu worked ... in San Diego, USA for 12 years. At ...
... Mylan Inc. (Nasdaq: MYL ) today ... with Biocon Limited, a publicly traded company on ... on the development, manufacturing, supply and commercialization of ... global marketplace. Through this partnership, Mylan and Biocon ...
... UPPSALA, Sweden, June 29 , ... Will Fund Gyros to Profitability , ... development, announces that it has raised SEK 80 million,(approximately euro ... Company,s leading shareholder. The new funds will enable Gyros to ...
Cached Biology Technology:Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 3Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 4Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4
(Date:7/9/2014)... Jena (Germany) They are amongst the most numerous inhabitants ... Emiliania huxleyi . Not visible to the naked eye, ... square kilometer sized patches, they are even visible on ... is responsible for approximately half of the global ... Friedrich Schiller University Jena (Germany). In the process the ...
(Date:7/9/2014)... they are used in the right ways. ... Hospital and coauthors analyzed six use cases with ... decompensation (when a patient,s condition worsens); adverse events; ... organ systems. They suspect that cost-savings benefits will ... all six scenarios will be significant. The authors ...
(Date:7/8/2014)... LAKE CITY, July 9, 2014 Collectors found the first ... in west Texas. Then, for two decades, the 14-inch-tall plant ... a third. , Now after a long search turned ... Utah botanist and her colleagues identified the spiny plant as ... heart" in Latin because it was found in Valentine, Texas, ...
Breaking Biology News(10 mins):Short circuit in the food web 2The impact of big data on health care: Health Affairs' July issue 2New plant species from the heart of Texas 2New plant species from the heart of Texas 3New plant species from the heart of Texas 4New plant species from the heart of Texas 5
... Space is not a fun place to get a stomach ... Utah chemists developed a two-minute water quality monitoring method that ... Station. "Now they bring water back on the space ... there is a big delay. You,d like to be able ...
... difference can a tenth of a nanometer make? When it ... resolution of that miniscule amount can mean the difference between ... Case in point: New, improved-resolution views of a zinc transporter ... Laboratory provide not just a structure but also a suggested ...
... stamp that can sniff out poisonous gases or deadly toxins ... 13 issue of the journal Nature Chemistry , Kenneth ... developed an artificial nose for the general detection of toxic ... and works by visualizing odors. This sensor array could ...
Cached Biology News:Water quality in orbit 2Water quality in orbit 3Water quality in orbit 4High-res view of zinc transport protein 2High-res view of zinc transport protein 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: